Novel Cancer Vaccination Technology

Engineered Immunotherapy for Cancer

Our mission is to help patients fight cancer

The ultimate goal of CyTuVax is to provide an effective treatment for patients with pancreatic cancer. CyTuVax has developed a revolutionary vaccination technology based on depot-attached cytokines. The adjuvant is capable of activating both the humoral and cellular arms of the immune system to induce powerful anti-tumor responses.
Rene Vleugels
Managing director

CyTuVax develops therapeutic vaccines against cancer and protective vaccines against viral & bacterial pathogens for which there is a high medical need. The patient is at the core in our vaccine development in which we apply our powerful adjuvant platform technology.

CyTuVax has developed a breakthrough, widely applicable and effective vaccination platform technology based on depot-attached cytokines as immune stimulator. The CyTuVax vaccines can generate powerful immune responses and are especially designed for cancer immunotherapy. The distinctive feature of our vaccine is a highly improved and prolonged antigen presentation by dendritic cells, which results in a stronger activation of immune cells.

The CyTuVax vaccination technology is a platform technology in several aspects. It can be applied with a wide range of cytokines aggregates as adjuvant and against a wide range of tumors. The vaccine has been successfully tested in preclinical studies with murine model tumors (fibro-sarcoma, melanoma, kidney, colon, mammary carcinoma and B-lymphoma). The effectiveness of the vaccination technology has also been verified in vaccines against viral targets (Hepatitis B) and bacterial targets (Antrax, Diphtheria and Tetanus).

CyTuVax is currently testing its vaccine technology in a clinical Phase 2 study of a vaccine for hepatitis B non-responders, persons that do not respond to standard hepatitis B vaccines. This clinical trial is being conducted with the Maastricht Universitair Medische Centrum (MUMC), Ziekenhuis Oost Limburg - Universiteit Hasselt, and Universiteit Antwerpen. More information about this clinical trial can be found at

Clinical Phase 2 Study - BE RESPONDER!

Hepatitis B HBAI20 vaccine for Non-responders

Cytuvax has completed the Phase 2 BE RESPONDER! clinical study to investigate the immunogenicity and safety of its Hepatitis B HBAI20 vaccine for Non-responders.

The double blinded multi-center international study was conducted at Maastricht University Medical Center, the Ziekenhuis Oost Limburg Genk - Hasselt University and the University of Antwerp under the responsibility of Dr. Astrid Oude Lashof, Dr. Geert Robaeys, and Prof. Pierre van Damme. The study started in February 2017 with the enrolment of the first volunteer. NCT03415672

Worldwide people are suffering from the effects of a hepatitis B virus (HBV) infection. HBV is a virus that can cause acute or chronic liver inflammation, which can lead to liver failure and liver cancer. The disease occurs in particular in Africa, South of the Sahara and in East Asia, where around 10% of the adults are chronic carriers of the virus. About 750,000 people worldwide die annually from the disease.
There are vaccinations available against HBV and these usually provide sufficient protection from HBV after 3 vaccinations. However, there is a small group of people (5% of the population) that does not respond to the standard HBV vaccination, the so-called non-responders.
For these non-responders CyTuVax developed the HBAI20 vaccine. The HBAI20 vaccine consists of a standard HBV vaccine to which the AI20 adjuvant is added. The adjuvant is able to give an additional stimulus to the immune system and may provide sufficient protection against HBV for the non-responders. In addition, the HBAI20 gives a faster protection offering the potential of less vaccinations in the future.


Latest news

showCyTuVax has shown the strength of its vaccine adjuvant technology in the Phase 2 clinical trial of a vaccine for hepatitis B non-responders
Press release 17-06-2019

Where we are

About us

CyTuVax B.V.
Oxfordlaan 55
6229 EV Maastricht
The Netherlands

Contact us by email